July 13, 2013Expert Opinion on Emerging Drugs
Emerging antithrombotic drugs for acute coronary syndrome
Why the study?
Do novel antithrombotic agents (cangrelor, vorapaxar, rivaroxaban) improve cardiovascular outcomes and mortality in patients with acute coronary syndrome compared to standard therapy?
Population
Patients with acute coronary syndrome, including acute myocardial infarction and unstable angina, and…
Comparison
Novel antithrombotic agents including cangrelor… vs Currently available antithrombotic agents.
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Balances ACS benefits against bleeding risks; leaves open optimal integration into current guidelines.
Structured PICO
Do novel antithrombotic agents (cangrelor, vorapaxar, rivaroxaban) improve cardiovascular outcomes and mortality in patients with acute coronary syndrome compared to standard therapy?
P
Population
Patients with acute coronary syndrome (ACS), including acute myocardial infarction (MI) and unstable angina, and patients with prior MI.
I
Intervention
Novel antithrombotic agents including cangrelor (intravenous P2Y12 receptor antagonist), vorapaxar (protease-activated receptor-1 inhibitor), and rivaroxaban (oral factor Xa inhibitor).
C
Comparator
Currently available antithrombotic agents (e.g., clopidogrel, standard oral antiplatelet therapy, placebo).
O
Outcome
Cardiovascular events, mortality, and safety (bleeding).
Novel antithrombotic agents such as cangrelor, vorapaxar, and rivaroxaban offer new therapeutic options for secondary prevention in ACS, though their use must be balanced against specific safety risks like bleeding.
Cite This Study
Shimada et al. (2013) studied this question.